Agilent Technologies introduces industry’s most sensitive GC/MSD system
![](/46/pdcnewsitem/03/76/79/agilent.png)
Pollutants and contaminants can now be detected at previously undetectable levels.
Agilent Technologies introduces the Agilent 5977B High Efficiency Source (HES) GC/MSD System, a tandem gas chromatograph and mass spectrometer that delivers lower limits of detection than any other instrument in its class.
“The 5977B is a major leap forward,” said Jim Yano, marketing vice president of Agilent’s Mass Spectrometry Division. “It includes a new high-efficiency ion source that makes it possible to detect pollutants and contaminants at previously undetectable levels.”
Agilent announced the breakthrough system at the Beijing Conference and Exposition on Instrumental Analysis, 27–30 October, an event the company has participated in since the conference began in 1985.
“The new system gives scientists the ability to detect trace levels of target compounds at levels 10 times lower than with any other single-quadrupole system,” Yano said. “Coupled with our MassHunter software, the 5977B is the most powerful GC/MSD ever.”
The Agilent 5977B will allow scientists to use smaller sample volume, spend less time on sample preparation, reduce instrument downtime, minimize solvent usage, and reduce the environmental impact of GC/MS analysis.
“Agilent supports scientists and researchers in their quest for answers and new discoveries through our technology, collaborations and insights,” said Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group. “Working closely with scientists in more than 100 countries, we deliver vital, actionable insights that advance our shared goal of creating a better world.”
In addition to the 5977B, Agilent is showcasing a wide range of solutions at the conference, including the following:
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance